Abstract
Mitoxantrone is an anthracenedione with structural similarities to doxorubicin [1]. Preclinical studies showed activity against a variety of experimental mouse leukemias both in vitro and in vivo, including partial activity against a subline of P388 leukemia resistant to doxorubicin [2–4]. Clinical trials with mitoxantrone in patients with relapsed and/or refractory acute leukemia have shown activity close to that seen with the anthracycline antibodies with a lower incidence of side effects [5–11]. In previously untreated patients with acute lymphatic leukemia (ALL) and acute nonlymphatic leukemia (ANLL), mitoxantrone has shown promise as a frontline treatment [11–14] or in combination with other chemotherapy agents in refractory leukemia [15–17].
This study was supported in part by a grant from the National Cancer Association of South Africa
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zee-Cheng RKY, Cheng CC (1978) Antineoplastic agents. Structure-activity relationship study of bis (substituted amino-alkylamino) anthraquinones. J Med Chem 21: 291–294
Cheng CC, Zbinden G, Zee-Cheng RKY (1979) Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics. J Pharm Sci 68: 393–396
Johnson RK, Zee-cheng RKY, Lee WW, Acton EM, Henry DW, Cheng CC (1979) Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63: 425–439
Wallace RE, Murdock KL, Angier RB, Duff FE (1979) Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis-[((2((2-hydroxyethyl) amino)ethyl)amino)]-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39: 1570–1574
Paciucci PA, Ohruma T, Cuttner J, Silver RT, Holland JF (1983) Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43: 3919–3922
Estey EH, Keating MH, McCreadie KB, Bodey GP, Freireich EJ (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67: 389–390
Prentice HG, Robbins G, Ma DDF, Ho AD (1984) Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11: 32–35
Paciucci PA, Cuttner J, Holland JF (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11: 36–40
Moore JO, Olsen GA (1984) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11: 41–46
Meyer P, Ho AD, Ehninger G, Mjaaland I, Heidemann E, Seither E (1985) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs 3: 203–206
Vorobiof DA, Falkson G, Coccia-Portugal MA, Terblanche APS (1987) Mitoxantrone in the treatment of acute leukemia. Invest New Drugs 5: 383–388
Van Echo DA, Schulman PN, Ferrari A, Budman D, Markus SD, Wiernik PH (1982) A phase II trial of mitoxantrone (DHAD.NSC 301739) in adult acute leukemia. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1: 132 (abstr)
Prentice HG, Robbins G, Ma DDF, Ho AD (1983) Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. Cancer Treat Rev 10: 57–63
Masaoka T, Shisata H, Oguma S, Nagai K, Kitani T, Horiuchi A, Yasunaga K, Yonezawa T, Kawagoe H (1985). A phase II study of mitoxantrone in acute leukemia. Invest New Drugs 3: 197–201
Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1986) High-dose cytosine- arabinoside and mitoxantrone in refractory acute myeloid leukemia: clinical phase I/II study. Onkologie 9: 144–146
Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T (1987) High dose cytosine-arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744–749
Hiddemann W, Kreutzmann H, Staif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder EV, Arlin Z, Büchner T (1987) High-dose cytosine-arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14: 73–77
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Coccia-Portugal, M.A., Falkson, G., Uys, A. (1990). Mitoxantrone in the Treatment of Acute Leukemia. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_59
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_59
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive